CHECKIT
John Wilson
CEO
We have worked with Yellowstone Advisory for a number of years and they transformed our investor relations strategy which significantly increased the interest of our business to both institutional and retail investors. We have been impressed by their understanding of the smaller companies market and their results focussed approach to IR. I would recommend their services without hesitation.
EQUINITI
Guy Wakeley
CEO
Yellowstone Advisory provided valuable input into the interim results announcement and presentation, helping to ensure the investment messaging was consistent throughout the documents. Great relationships and credibility with investors enables them to solicit useful feedback which we have used in developing our future investor messaging.
Private Investor Evening - Monday 4th November
Mon, 04 Nov
|City of London location. TBD
Our next private investor evening will be held in London on Monday 4th November starting at 5.30pm until 8.00pm. Checkit (previously Elektron Technology), MIRRIAD, Volex and Allergy Therapeutics will all be attending. Company management presentations and Q&A sessions. Followed by refreshments.
Time & Location
04 Nov 2019, 17:30 – 20:00
City of London location. TBD
Guests
About the event
Checkit (previously Elektron Technology), Mirriad, Volex and Allergy Therapeutics management are all presenting.
Checkit plc: [CKT LN)] Checkit (previously Elektron Technology) creates and develops products and services that Connect, Monitor and Control. Checkit is an early stage high growth business that provides a real-time operations management system.
MIRRIAD plc: [MIRI LN] Mirriad analyses and identifies brand insertion opportunities in entertainment content and partners with broadcasters and digital publishers to deliver in-video advertising.
Volex plc: A leading global supplier of cable assembly solution servicing a diverse range of markets including consumer electronics, telecoms, data centres, medical equipment and the automotive industry.
Allergy Therapeutics plc (AGY LN): A pioneering market leader in immunology with specialist experience in the research and development of allergy treatments. Focus on the direct treatment of the cause rather than just managing symptoms. Aluminium free vaccines with ultra-short course treatments to increase adherence.